[Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer].


Ninety-six patients with unresectable or metastatic colorectal cancer received first-line chemotherapy plus bevacizumab. The purpose of our study was to evaluate the safety and efficacy of the therapy. Median relapse-free survival lasted 10.4 months. Addition of bevacizumab was well tolerated and may be recommended for clinical use. 


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.